AICAR vs Omentin-1
Head-to-head comparison of AICAR (5-Aminoimidazole-4-carboxamide Ribonucleotide (Acadesine)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | AICAR | Omentin-1 |
|---|---|---|
| Category | Performance | Diabetes & Metabolic |
| Full Name | 5-Aminoimidazole-4-carboxamide Ribonucleotide (Acadesine) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 338.21 g/mol | ~35 kDa |
| Half-Life | ~2-3 hours | hours |
| Amino Acids | Nucleoside analog | 313 |
| Typical Dose | — | No approved human dose; research use only |
| Route | — | IV|SC |
| Purity | >99% | ≥98% |
| Studies Count | 180 | 82 |
| Research Status | Active Research | Pre-clinical |
AICAR Benefits
- ✓Increases endurance capacity, enhances fatty acid oxidation, promotes mitochondrial biogenesis, improves glucose uptake, cardioprotective effects
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
AICAR Dosing
Research doses: 50-150 mg subcutaneously. Typically administered 30-60 minutes before physical activity in research settings.
Omentin-1 Dosing
not established|not established
AICAR Side Effects
- ⚠Potential hypoglycemia, lactic acidosis at high doses, injection site reactions. Banned by WADA as a metabolic modulator.
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
AICAR
Salk Institute researchers demonstrated AICAR could increase endurance in sedentary mice by 44% without exercise training. Activates AMPK, triggering PGC-1α expression, mitochondrial biogenesis, and enhanced fatty acid β-oxidation.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.